Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Menée à partir des données de deux essais cliniques portant sur 148 patients atteints d'un cancer du poumon métastatique non à petites cellules (durée médiane de suivi : 33 mois), cette étude évalue l'intérêt, du point de vue de la survie sans progression et de la survie globale, d'ajouter une radiothérapie à un traitement par pembrolizumab

Résumé en anglais

Background : Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab) with or without radiotherapy. When the trials were analysed individually, a potential benefit was noted in the combination treatment arm. However, owing to the small sample size of each trial, differences in response rates and outcomes were not statistically significant but remained clinically notable. We therefore did a pooled analysis to infer whether radiotherapy improves responses to immunotherapy in patients with metastatic non-small-cell lung cancer.

Methods : Inclusion criteria for the PEMBRO-RT and MDACC trials were patients (aged